Gene and Cellular Immunotherapy for Cancer

ISBN-13: 9783030878511 / Angielski / Miękka / 2022 / 378 str.

Armin Ghobadi; John F. Dipersio

Opis

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more.  Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.

Spis treści

Part I: Overview

1.  The History of Cellular Therapies

 2. Basics of Immunity 

Part II: CAR-T

3. Biology of CAR-T

4. Cell Types Used for CAR-T Generation

5. Combination Therapeutics with CAR-T Cell Therapy

6. Safety Switches Used for Cellular Therapies

7. Off the Shelf CAR-T

8. Manufacturing of CAR-T Cells: the Assembly Line

9. Navigating Regulations in Gene and Cell Immunotherapy

10. Bringing CAR-T to the Clinic

11. CAR-T Cell Complications

12. Mechanisms of Resistance and Relapse after CAR-T Cell Therapy

 

Part III: TIL

13. Tumor Infiltrating Lymphocytes (TIL): From Bench to Bedside

 

Part IV: TCR

14. T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic

 

Part V: Viral CTLs

15. Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside

Part VI: NK Cell

16. Biology of NK Cells and NK Cells in Clinic

 

Part VII: T/NK cell engagers

17. Biology and Clinical Evaluation of T/NK Cell Engagers

 

Part VIII: Logistics

18. Roadmap for Starting an Outpatient Cellular Therapy Program

O autorze

Armin Ghobadi is an Associate Professor in the Division of Oncology and clinical director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine in St. Louis, and a member of the Alvin J. Siteman Cancer Center. He earned his Medical Diploma at Iran University of Medical Sciences and Health Services School of Medicine in Tehran. Ghobadi’s post graduate training has been at the University of Texas Southwestern Medical School in Dallas, TX, the MD Anderson Cancer Center in Houston, TX and Washington University School of Medicine in St. Louis. Currently his research focuses on cellular therapy for hematologic malignancies, hematopoietic stem cell transplantation, and genome sequencing

 

John F. DiPersio is the Deputy Director of Alvin J. Siteman Cancer Center, Samuel J. Goldman Endowed Professor of Oncology, Chief of the Division of Oncology, and director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine inSt. Louis. DiPersio earned a BA in Biology at Williams College in Williamstown, MA and a Ph.D./MD in Microbiology at the University of Rochester, Rochester, NY. Currently, his research focuses on hematopoietic stem cell mobilization, murine models of graft-versus host disease and graft-versus leukemia, leukemia genomics and targeted cellular therapies for the treatment of leukemias.